ADU-S100 is a suspected disease in the field of blood tumours, with clinical performance being complex and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching the needs of a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HL along with ADU-S100. The platform serves a team of domestic and international experts in the field of blood tumour systems in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.